Liver Diseases pp 721-726 | Cite as

Extracorporeal Cellular Liver Assisted Devices

  • Pavan Patel
  • Nikolaos T. PyrsopoulosEmail author


The current definitive management of acute liver failure and acute on chronic liver failure is liver transplantation. However, because of organ shortages, other modalities of therapy are necessary as a possible bridge. This chapter discusses the current state of extracorporeal cellular (bioartificial) liver assist devices including Extracorporeal Liver Assist Device (ELAD), HepatAssist, Modular Extracorporeal Liver Support System (MELS), and the Bioartificial Liver Support System (BLSS). An overview of the circuit as well as outcomes of studies done using these devices will be provided.


Liver assist device Bioartificial liver assist device Extracorporeal liver assist device (ELAD) HepatAssist Modular extracorporeal liver support system (MELS) Bioartificial liver support system (BLSS) Acute liver failure 


  1. 1.
    Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51:1675. Scholar
  2. 2.
    Rahman H. Review article: liver support systems in acute hepatic failure. Aliment Pharmacol Ther. 1999;13(10):1255–72. Scholar
  3. 3.
    Riordan SM, Williams R. Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis. J Gastroenterol Hepatol. 1999;14(8):757–70. Scholar
  4. 4.
    Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology. 2001;34(3):447–55. Scholar
  5. 5.
    Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology. 2001;120(3):749–62. Scholar
  6. 6.
    Pless G. Artificial and bioartificial liver support. Organogenesis. 2007;3:20. Scholar
  7. 7.
    van Wenum M, Chamuleau RA, van Gulik TM, Siliakus A, Seppen J, Hoekstra R. Bioartificial livers in vitro and in vivo : tailoring biocomponents to the expanding variety of applications. Expert Opin Biol Ther. 2014;14:1745. Scholar
  8. 8.
    Leckie P, Davenport A, Jalan R. Extracorporeal liver support. Blood Purif. 2012;34(2):158–63. Scholar
  9. 9.
    Chen HS, Nyberg SL. Acute liver failure and bioartificial liver support. 8th ed. Amsterdam: Elsevier Inc.; 2018. Scholar
  10. 10.
    Thompson J, Jones N, Al-Khafaji A, et al. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial. Liver Transpl. 2018;24:380. Scholar
  11. 11.
    Gislason GT, Lobdell DD, Kelly JH, Sussman NL. A treatment system for implementing an extracorporeal liver assist device. Artif Organs. 1994;18(5):385–9. Scholar
  12. 12.
    Tritto G, Davies N, Jalan R. Liver replacement therapy. Semin Respir Crit Care Med. 2012;33:70. Scholar
  13. 13.
    Millis JM, Cronin DC, Johnson R, et al. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation. 2002;74(12):1735–46. Scholar
  14. 14.
    Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology. 1996;24(6):1446–51. Scholar
  15. 15.
    Sussman NL, Kelly JH. Improved liver function following treatment with an extracorporeal liver assist device. Artif Organs. 1993;17:27. Scholar
  16. 16.
    Duan Z, Xin S, Zhang J, et al. Comparison of extracorporeal cellular therapy (ELAD) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure. Hepatic Med Evid Res. 2018;10:139–52. Scholar
  17. 17.
    Landeen LK, Lapetoda J, Bedard PW, et al. Sa1449 - inflammation biomarkers decrease during ELAD treatment in alcoholic hepatitis subjects. Gastroenterology. 2018;154(6):S–1117. Scholar
  18. 18.
    Demetriou AA, Brown RS, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004;239(5):660–70. Scholar
  19. 19.
    Watanabe FD, Mullon CJ, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg. 1997;225(5):484–91-4. Scholar
  20. 20.
    Sauer IM, Kardassis D, Zeillinger K, et al. Clinical extracorporeal hybrid liver support--phase I study with primary porcine liver cells. Xenotransplantation. 2003;10:460–9. Scholar
  21. 21.
    Gerlach JC, Encke J, Hole O, Müller C, Ryan CJ, Neuhaus P. Bioreactor for a larger scale hepatocyte in vitro perfusion. Transplantation. 1994;58:984. Scholar
  22. 22.
    Sauer IM, Zeilinger K, Pless G, et al. Extracorporeal liver support based on primary human liver cells and albumin dialysis - treatment of a patient with primary graft non-function. J Hepatol. 2003;39:649. Scholar
  23. 23.
    Sauer IM, Zeilinger K, Obermayer N, et al. Primary human liver cells as source for modular extracorporeal liver support--a preliminary report. Int J Artif Organs. 2002;25:1001.CrossRefGoogle Scholar
  24. 24.
    Patzer JF, Mazariegos GV, Lopez R, et al. Novel bioartificial liver support system: preclinical evaluation. Ann N Y Acad Sci. 1999;875:340–52. Scholar
  25. 25.
    Mazariegos GV, Patzer JF, Lopez RC, et al. First clinical use of a novel Bioartificial Liver Support System (BLSS). Am J Transplant. 2002;2(3):260–6. Scholar
  26. 26.
    Mazariegos GV, Kramer DJ, Lopez RC, et al. Safety observations in Phase I clinical evaluation of the excorp medical bioartificial liver support system after the first four patients. ASAIO J. 2001;47(5):471–5. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyRutgers—New Jersey Medical SchoolNewarkUSA

Personalised recommendations